Carla de Boer

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2019, Clinical Lymphoma Myeloma and Leukemia.

Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.

P. Sonneveld, M. Béné, P. Moreau, 2019, Journal of Clinical Oncology.

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

P. Sonneveld, P. Moreau, X. Leleu, 2019, Blood.

Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

Breast and Squamous Cell Carcinomas Encompasses Three CpG Islands Telomeric of FGF3, Including the Expressed Gene

G. Peters, S. Brookes, R. Michalides, 2006 .